Vericel Corporation (NASDAQ: VCEL) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Earnings & Valuation

This table compares Vericel Corporation and Catalyst Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Vericel Corporation $53.77 million 3.66 -$20.03 million ($1.10) -5.45
Catalyst Biosciences $561,999.00 38.81 -$19.79 million ($17.78) -0.28

Catalyst Biosciences has higher revenue, but lower earnings than Vericel Corporation. Vericel Corporation is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vericel Corporation and Catalyst Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vericel Corporation -50.27% N/A -59.46%
Catalyst Biosciences -3,127.92% -92.61% -46.69%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Vericel Corporation and Catalyst Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel Corporation 0 0 3 0 3.00
Catalyst Biosciences 0 0 3 0 3.00

Vericel Corporation currently has a consensus price target of $6.33, suggesting a potential upside of 5.56%. Catalyst Biosciences has a consensus price target of $24.50, suggesting a potential upside of 384.19%. Given Catalyst Biosciences’ higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Vericel Corporation.

Insider and Institutional Ownership

33.8% of Vericel Corporation shares are owned by institutional investors. Comparatively, 29.2% of Catalyst Biosciences shares are owned by institutional investors. 3.3% of Vericel Corporation shares are owned by insiders. Comparatively, 5.0% of Catalyst Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Vericel Corporation has a beta of 3.16, suggesting that its stock price is 216% more volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500.

Summary

Vericel Corporation beats Catalyst Biosciences on 6 of the 11 factors compared between the two stocks.

About Vericel Corporation

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

About Catalyst Biosciences

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.